312 related articles for article (PubMed ID: 17223917)
1. Detection and follow-up of fibroblast growth factor receptor 3 expression on bone marrow and circulating plasma cells by flow cytometry in patients with t(4;14) multiple myeloma.
Chandesris MO; Soulier J; Labaume S; Crinquette A; Repellini L; Chemin K; Malphettes M; Fieschi C; Asli B; Uzunhan Y; Fermand JP; Bories JC; Arnulf B
Br J Haematol; 2007 Feb; 136(4):609-14. PubMed ID: 17223917
[TBL] [Abstract][Full Text] [Related]
2. A global expression-based analysis of the consequences of the t(4;14) translocation in myeloma.
Dring AM; Davies FE; Fenton JA; Roddam PL; Scott K; Gonzalez D; Rollinson S; Rawstron AC; Rees-Unwin KS; Li C; Munshi NC; Anderson KC; Morgan GJ
Clin Cancer Res; 2004 Sep; 10(17):5692-701. PubMed ID: 15355895
[TBL] [Abstract][Full Text] [Related]
3. Detection of t(4;14)(p16.3;q32) chromosomal translocation in multiple myeloma by reverse transcription-polymerase chain reaction analysis of IGH-MMSET fusion transcripts.
Malgeri U; Baldini L; Perfetti V; Fabris S; Vignarelli MC; Colombo G; Lotti V; Compasso S; Bogni S; Lombardi L; Maiolo AT; Neri A
Cancer Res; 2000 Aug; 60(15):4058-61. PubMed ID: 10945609
[TBL] [Abstract][Full Text] [Related]
4. FGFR3 is expressed and is important for survival in INA-6, a human myeloma cell line without a t(4;14).
Våtsveen TK; Brenne AT; Dai HY; Waage A; Sundan A; Børset M
Eur J Haematol; 2009 Nov; 83(5):471-6. PubMed ID: 19594619
[TBL] [Abstract][Full Text] [Related]
5. Translocation T(4;14)(p16.3;q32) is a recurrent genetic lesion in primary amyloidosis.
Perfetti V; Coluccia AM; Intini D; Malgeri U; Vignarelli MC; Casarini S; Merlini G; Neri A
Am J Pathol; 2001 May; 158(5):1599-603. PubMed ID: 11337357
[TBL] [Abstract][Full Text] [Related]
6. Deregulated FGFR3 mutants in multiple myeloma cell lines with t(4;14): comparative analysis of Y373C, K650E and the novel G384D mutations.
Ronchetti D; Greco A; Compasso S; Colombo G; Dell'Era P; Otsuki T; Lombardi L; Neri A
Oncogene; 2001 Jun; 20(27):3553-62. PubMed ID: 11429702
[TBL] [Abstract][Full Text] [Related]
7. Novel mutation and RNA splice variant of fibroblast growth factor receptor 3 in multiple myeloma patients at diagnosis.
Soverini S; Terragna C; Testoni N; Ruggeri D; Tosi P; Zamagni E; Cellini C; Cavo M; Baccarani M; Tura S; Martinelli G
Haematologica; 2002 Oct; 87(10):1036-40. PubMed ID: 12368157
[TBL] [Abstract][Full Text] [Related]
8. In multiple myeloma, t(4;14)(p16;q32) is an adverse prognostic factor irrespective of FGFR3 expression.
Keats JJ; Reiman T; Maxwell CA; Taylor BJ; Larratt LM; Mant MJ; Belch AR; Pilarski LM
Blood; 2003 Feb; 101(4):1520-9. PubMed ID: 12393535
[TBL] [Abstract][Full Text] [Related]
9. A subset of multiple myeloma harboring the t(4;14)(p16;q32) translocation lacks FGFR3 expression but maintains an IGH/MMSET fusion transcript.
Santra M; Zhan F; Tian E; Barlogie B; Shaughnessy J
Blood; 2003 Mar; 101(6):2374-6. PubMed ID: 12433679
[TBL] [Abstract][Full Text] [Related]
10. Expression of fibroblast growth factor and FGF-receptor family genes in human myeloma cells, including lines possessing t(4;14)(q16.3;q32. 3) and FGFR3 translocation.
Otsuki T; Yamada O; Yata K; Sakaguchi H; Kurebayashi J; Nakazawa N; Taniwaki M; Yawata Y; Ueki A
Int J Oncol; 1999 Dec; 15(6):1205-12. PubMed ID: 10568829
[TBL] [Abstract][Full Text] [Related]
11. [Detection of IgH-MMSET fusion gene in multiple myeloma patients and its significance].
Jiang H; Hou J; Chen YB; Ding SQ
Zhonghua Xue Ye Xue Za Zhi; 2003 Oct; 24(10):515-8. PubMed ID: 14690579
[TBL] [Abstract][Full Text] [Related]
12. Differential nuclear organization of translocation-prone genes in nonmalignant B cells from patients with t(14;16) as compared with t(4;14) or t(11;14) myeloma.
Martin LD; Harizanova J; Righolt CH; Zhu G; Mai S; Belch AR; Pilarski LM
Genes Chromosomes Cancer; 2013 Jun; 52(6):523-37. PubMed ID: 23460268
[TBL] [Abstract][Full Text] [Related]
13. Interphase fluorescence in situ hybridization in multiple myeloma and monoclonal gammopathy of undetermined significance without and with positive plasma cell identification: analysis of 192 cases from the Region of Southern Denmark.
Christensen JH; Abildgaard N; Plesner T; Nibe A; Nielsen O; Sørensen AG; Kerndrup GB;
Cancer Genet Cytogenet; 2007 Apr; 174(2):89-99. PubMed ID: 17452249
[TBL] [Abstract][Full Text] [Related]
14. Bortezomib, dexamethasone, and fibroblast growth factor receptor 3-specific tyrosine kinase inhibitor in t(4;14) myeloma.
Bisping G; Wenning D; Kropff M; Gustavus D; Müller-Tidow C; Stelljes M; Munzert G; Hilberg F; Roth GJ; Stefanic M; Volpert S; Mesters RM; Berdel WE; Kienast J
Clin Cancer Res; 2009 Jan; 15(2):520-31. PubMed ID: 19147757
[TBL] [Abstract][Full Text] [Related]
15. Chromosomal translocations t(4;14), t(11;14) and proliferation rate stratify patients with mature plasma cell myelomas into groups with different survival probabilities: a molecular epidemiologic study on tissue microarrays.
Tinguely M; Jenni B; Reineke T; Korol D; Kofler A; Rousson V; Dommann-Scherrer C; Maurer R; Moch H; Probst-Hensch NM
Am J Surg Pathol; 2007 May; 31(5):690-6. PubMed ID: 17460451
[TBL] [Abstract][Full Text] [Related]
16. CHIR-258 is efficacious in a newly developed fibroblast growth factor receptor 3-expressing orthotopic multiple myeloma model in mice.
Xin X; Abrams TJ; Hollenbach PW; Rendahl KG; Tang Y; Oei YA; Embry MG; Swinarski DE; Garrett EN; Pryer NK; Trudel S; Jallal B; Mendel DB; Heise CC
Clin Cancer Res; 2006 Aug; 12(16):4908-15. PubMed ID: 16914579
[TBL] [Abstract][Full Text] [Related]
17. A molecular study of the t(4;14) in multiple myeloma.
Sibley K; Fenton JA; Dring AM; Ashcroft AJ; Rawstron AC; Morgan GJ
Br J Haematol; 2002 Aug; 118(2):514-20. PubMed ID: 12139740
[TBL] [Abstract][Full Text] [Related]
18. The t(4;14) translocation in myeloma dysregulates both FGFR3 and a novel gene, MMSET, resulting in IgH/MMSET hybrid transcripts.
Chesi M; Nardini E; Lim RS; Smith KD; Kuehl WM; Bergsagel PL
Blood; 1998 Nov; 92(9):3025-34. PubMed ID: 9787135
[TBL] [Abstract][Full Text] [Related]
19. CD221 (IGF-1R) is aberrantly expressed in multiple myeloma, in relation to disease severity.
Bataille R; Robillard N; Avet-Loiseau H; Harousseau JL; Moreau P
Haematologica; 2005 May; 90(5):706-7. PubMed ID: 15921396
[TBL] [Abstract][Full Text] [Related]
20. Targeting FGFR3 in multiple myeloma: inhibition of t(4;14)-positive cells by SU5402 and PD173074.
Grand EK; Chase AJ; Heath C; Rahemtulla A; Cross NC
Leukemia; 2004 May; 18(5):962-6. PubMed ID: 15029211
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
